Efficient lowering of blood cholesterol is pivotal in reducing the risk for heart attack and stroke, the most frequent causes of death globally. Different cholesterol-lowering drugs are available, but it is difficult to find an optimal treatment strategy for each person, resulting in suboptimal treatment and an increased risk for heart attack and stroke for many patients. The Moncyte analysis tool sheds light on why individuals respond differently to cholesterol-lowering medication. This will enable novel personalized treatment strategies, helping more patients to achieve their blood cholesterol target levels and reducing cardiovascular morbidity and mortality.

 

  • Founding year:
  • Currently R2B project that started 1 July, 2021
  • Development phase:
  • Proof-of-concept
  • Funding stage:
  • Pre-seed in 2023
  • Website:
  • Contact person info:
  • tamara.alagirova(at)helsinki.fi
  • Team members:
  • 4